Sign in

What researchers published on Myasthenia gravis

5,934 papers, newest first.

Showing 20 of 144

  • Trial resultLong-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).Frontiers in neurology
  • Randomised trialEfficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.Expert opinion on biological therapy
  • Randomised trialManagement of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial.JAMA neurology
  • Randomised trialEfficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.JAMA neurology
  • Randomised trialHospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.Journal of medical economics
  • Randomised trialUsability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.Advances in therapy
  • Randomised trialHealth-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.Journal of neurology
  • Randomised trialProteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.Journal of translational medicine
  • Randomised trialPathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.Journal of neurology, neurosurgery, and psychiatry
  • Randomised trialClinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).Journal of neurology
  • Randomised trialEvaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.European journal of neurology
  • Trial resultPhase 1 dose-finding study of topical neostigmine ophthalmic solution for alleviating myasthenic ptosis.Scientific reports
  • Randomised trialEfficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.JAMA neurology
  • Randomised trialEfficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet (London, England)
  • Randomised trialImpact of a ketogenic diet on clinical outcomes and immunological markers in myasthenia gravis: A randomized pilot study.Journal of autoimmunity
  • Randomised trialDigital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG-MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue.Muscle & nerve
  • Randomised trialEfficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.Neurology
  • Randomised trialEfficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.Neurology
  • Randomised trialEfficacy and safety of efgartigimod in the treatment of impending myasthenic crisis.Frontiers in immunology
  • Trial resultSingle-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy.Med (New York, N.Y.)